- Home
- USEA vs TPST Comparison
USEA vs TPST Comparison
Compare USEA & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | TPST |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 15.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | USEA | TPST |
|---|---|---|
| Price | $1.70 | $2.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 39.0K | ★ 84.9K |
| Earning Date | 03-17-2026 | 11-05-2025 |
| Dividend Yield | ★ 7.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $42,025,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $2.26 |
| 52 Week High | $2.22 | $12.48 |
Technical Indicators
Market Signals| Indicator | USEA | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 36.69 | 28.87 |
| Support Level | $1.69 | $2.55 |
| Resistance Level | $1.99 | $3.00 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 3.85 | 4.08 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company. It is engaged in seaborne transportation services. The group currently operates a fleet of five dry bulk vessels, comprising two Kamsarmax and three Panamax vessels with an aggregate cargo-carrying capacity of approximately 396,297 dwt.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.